The short version of Tesamorelin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-11. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
The amount of UV radiation produced by the Sun means that the Earth would not be able to sustain life on dry land if most of that light were not filtered out by the atmosphere. UV light from the Sun at wavelengths shorter than approximately 300 nm is absorbed in the atmosphere, primarily by ozone and molecular oxygen, before it reaches the ground. However, UV (specifically, UVB) is also responsible for the formation of vitamin D in most land vertebrates, including humans. The UV spectrum, thus, has effects both beneficial and detrimental to life. The lower wavelength limit of the visible spectrum is conventionally taken as 400 nm. Although ultraviolet rays are not generally visible to humans, 400 nm is not a sharp cutoff, with shorter and shorter wavelengths becoming less and less visible in this range. Insects, birds, and some mammals can see near-UV (NUV), because they can see somewhat shorter wavelengths than what humans can see.
== Use in sport == Lipotropin is on the Prohibited List of substances by the World Anti Doping Agency. Lipotropin has also, under its alternate name AOD-9604 (Anti-Obesity Drug-9604), been connected with controversies in Australian Rules Football. Allegations have arisen around the use of the drug and its administration to players of the Essendon Football Club in the Essendon Football Club supplements saga, including weekly administration to players in the 2012 season. The matters are currently under investigation due to the relationship between Lipotropin and growth hormones, as noted by club medical staff.
=== Anti-angiogenic drugs === Osteonecrosis of the jaw has been identified as one of the possible complications of taking anti-angiogenic drugs; the association of the disease with the medication is known as MRONJ. This has been stated in the Drug Safety Updates by the MHRA. Angiogenesis inhibitors interfere with blood vessel formation by interfering with the angiogenesis signalling cascade. They are used primarily to treat cancer. These cancer-fighting agents tend to hinder the growth of blood vessels that supply the tumour, rather than killing tumour cells directly. They prevent the tumour from growing. For example, bevacizumab/aflibercept is a monoclonal antibody that specifically binds to vascular endothelial growth factor (VEGF), preventing VEGF from binding to receptors on the surface of normal endothelial cells. Sunitinib is a different example of an anti-angiogenic drug; it inhibits cellular signalling by targeting multiple receptor tyrosine kinases. It reduces the blood supply to the tumour by inhibiting new blood vessel formation in the tumor. The tumour may stop growing or even shrink.
== Haemovigilance == Haemovigilance is the set of surveillance procedures that monitors, reports, investigates, and analyses adverse events related to transfusion. It covers the entire blood transfusion chain, from blood donation and processing of blood and its components, through to their provision and transfusion to patients. These reporting systems play a fundamental role in enhancing patient safety by learning from failures and then putting system changes in place to prevent them in the future. The TP's involvement in haemovigilance within the hospital setting, starts with education of those involved in the transfusion process so they can recognise, manage, and report reactions. The TPs roles ensures clinical transfusion incidents, transfusion reactions, specimen labelling errors are investigated and report data to haemovigilance governance programmes (e.g. SHOT in the UK). By conducting process reviews and communicating directly with the relevant colleagues and patients, the TP can provide essential details that are needed to complete investigations. This information can assist with determining the transfusion reaction type and recommendations for future transfusion plans for the patient, or the implementation of corrective and preventative measures. National haemovigilance schemes e.g. SHOT provide the TP with a resource for educating clinical colleagues on transfusion safety and recommendations for best practice.
Sources: en.wikipedia.org
=== Vitamin k metabolism === The enzyme is also involved in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. NQO1 catalyzes the reduction of vitamin K1, K2 and K3 into their hydroquinone form, but it only has a high affinity for Vitamin K3. Vitamin K hydroquinone serves as a cofactor for vitamin K γ‐carboxylase that catalyzes γ‐carboxylation of specific glutamic acid residues in Gla‐factors/proteins (Gla domain) leading to their activation and participation in blood clotting and bone metabolism. Vitamin K is used as radiation sensitizer or in mixtures with other chemotherapeutic drugs to treat several types of cancer. ROS generated in redox cycling contributes to anticancer activity of vitamin K. NQO1 competes with enzymes that redox cycle vitamin K to formation of semiquinone and ROS. NQO1is therefore able to detoxify vitamin K3 and protect cells against oxidative stress.
== Long-term potentiation == Calcium/ calmodulin dependent protein kinase II is also heavily implicated in long-term potentiation (LTP) – the molecular process of strengthening active synapses that is thought to underlie the processes of memory. It is involved in many aspects of this process. LTP is initiated when the NMDA receptors are in a local environment with a voltage potential high enough to displace the positively-charged Mg2+ ion from the channel pore. As a result of the channel being unblocked, Ca2+ ions are able to enter into the postsynaptic neuron through the NMDA receptor channel. This Ca2+ influx activates CaMKII. It has been shown that there is an increase in CaMKII activity directly in the post synaptic density of dendrites after LTP induction, suggesting that activation is a direct result of stimulation.
In the final, Zverev defeated Flavio Cobolli in a five-set contest, his longest match of the tournament by duration and sets played. With his win, Zverev became the first German men's singles champion since Henner Henkel in 1937, ending an 89 year drought. He became the first German male to win a major since Boris Becker in 1996 and joined Michael Stich and Becker to become the third German men's singles player to win a Major. In addition, he became the first player, male or female, to win a Major with Type 1 diabetes. Zverev rejoined the tour in Halle, reaching the semifinals just dropping one set to Vit Kopřiva in the second round. He lost the semifinal match to eventual finalist Taylor Fritz despite winning the first set, extending his ongoing losing streak against the American since Wimbledon 2024 to seven consecutive losses. During the 2026 Wimbledon, Zverev reached back-to-back second weeks of a major, and after defeating this time Taylor Fritz in the quarterfinal, and Arthur Fery in the semifinal, he made it to his second consecutive appearance in a Grand Slam final.. In the final, he lost to Sinner in four sets. Zverev lost his second round match to Tallon Griekspoor at the National Bank Open in 3 sets, then lost his 4th round match at the Cincinnati Masters to Tommy Paul in 3 sets. During the 2026 US Open, Zverev entered as the first seed following Jannik Sinner's withdrawal due to a knee injury. He nearly suffered a first-round defeat, being 2 points away from losing to Lorenzo Sonego in the 4th set while down two sets to one, and serving at 4-5, 30-30.
The North American Hetman movement reached the height of its influence around 1937–1938, when it was visited by Danylo Skoropadskyi, the hetman's son and successor. However, the organizations lost their influence during WW2 and in the following years due to internal splits and government investigations into their activity.
The enzyme is bifunctional and in the reverse direction is equivalent to glutathionylspermidine amidase, which hydrolyses the product back to the starting materials. This enzyme is a ligase, specifically one forming carbon-nitrogen bonds as acid-D-ammonia (or amine) ligases (amide synthases). The systematic name of this enzyme class is gamma-L-glutamyl-L-cysteinyl-glycine:spermidine ligase (ADP-forming) [spermidine is numbered so that atom N-1 is in the amino group of the aminopropyl part of the molecule]. This enzyme is also called glutathione:spermidine ligase (ADP-forming). This enzyme participates in glutathione metabolism. It uses magnesium as a cofactor.
Sources: en.wikipedia.org
A botanical drug is defined in the United States Federal Food, Drug, and Cosmetic Act as a botanical product that is marketed as diagnosing, mitigating, treating, or curing a disease; a botanical product in turn, is a finished, labeled product that contains ingredients from plants. Chemicals that are purified from plants, like paclitaxel, and highly purified products of industrial fermentation, like biopharmaceuticals, are not considered to be botanical products. In 2006 the Food and Drug Administration approved the first botanical drug in the United States: sinecatechins, a green tea extract for genital warts.
The second tier consists of several dozens of midsized companies, with sales in the range of $100–$250 million per year. Their portfolios comprise both custom manufacturing and API-for-generics. They include both independents and subsidiaries of major companies. A number of these companies are privately owned and have grown mainly by reinvesting the profits. Examples are Bachem, Switzerland; Dishman, India; F.I.S. and Poli Industria Chimica, Italy; Hikal, India, and Hovione, Portugal. Customers prefer to do business with mid-sized companies, because communications are easier — they typically deal directly with the decision maker — and they can better leverage their purchasing power. The third tier includes thousands of small independents, with sales below $100 million per year. Most of them are located in Asia. They often specialize in niche technologies. The minimum economical size of a fine chemical company depends on the availability of infrastructure. If a company is located in an industrial park, where analytical services, utilities, safety, health, and environmental (SHE) services, and warehousing are readily available, there is practically no lower limit. New fine chemical plants have appeared mostly in Far East countries over the past few years. Their annual turnover rate rarely exceeds $25 million. All big and medium-size fine chemical companies have cGMP-compliant plants that are suitable for the production of pharmaceutical fine chemicals.
== Description == Typical Catostylus with chunky appendages and tentacle to go with each. This jellyfish has a sting that causes light pain and a skin rash, but generally poses no serious threat. It is up to 65 cm (26 in) in bell diameter, but a more typical size is 25 cm (10 in) in diameter and 2.5 kg (5.5 lb) in weight. Its colour is variable and can be blue-white, cream, brown, or off-white. The exumbrellar grooves are reddish or purplish brown. C. tagi has gonads along the edge of its stomach in an X shape. It has the octant formation typical of Catostylus jellies, the height of the octants are also variable.
== Sources == Schmitt, Michael; Mayerhöfer, Thomas; Popp, Jürgen; Kleppe, Ingo; Weisshartannée, Klaus (2013). Handbook of Biophotonics, Chap.3 Light–Matter Interaction. Wiley. doi:10.1002/9783527643981.bphot003. ISBN 978-3-527-64398-1. S2CID 93908151. Pavone, Francesco S.; Campagnola, Paul J. (2016). Second Harmonic Generation Imaging, 2nd edition. CRC Taylor&Francis. ISBN 978-1-4398-4914-9. Campagnola, Paul J.; Clark, Heather A.; Mohler, William A.; Lewis, Aaron; Loew, Leslie M. (2001). "Second harmonic imaging microscopy of living cells" (PDF). Journal of Biomedical Optics. 6 (3): 277–286. Bibcode:2001JBO.....6..277C. doi:10.1117/1.1383294. hdl:2047/d20000323. PMID 11516317. S2CID 2376695. Campagnola, Paul J.; Loew, Leslie M (2003). "Second-harmonic imaging microscopy for visualizing biomolecular arrays in cells, tissues and organisms" (PDF). Nature Biotechnology. 21 (11): 1356–1360. doi:10.1038/nbt894. PMID 14595363. S2CID 18701570. Archived from the original (PDF) on 2016-03-04. Stoller, P.; Reiser, K.M.; Celliers, P.M.; Rubenchik, A.M. (2002). "Polarization-modulated second harmonic generation in collagen". Biophys. J. 82 (6): 3330–3342. Bibcode:2002BpJ....82.3330S. doi:10.1016/s0006-3495(02)75673-7. PMC 1302120. PMID 12023255. Han, M.; Giese, G.; Bille, J. F. (2005). "Second harmonic generation imaging of collagen fibrils in cornea and sclera". Opt. Express. 13 (15): 5791–5797. Bibcode:2005OExpr..13.5791H. doi:10.1364/opex.13.005791. PMID 19498583. König, Karsten (2018). Multiphoton Microscopy and Fluorescence Lifetime Imaging - Applications in Biology and Medicine.
=== Industrial === Food: Biopolymers are being used in the food industry for things like packaging, edible encapsulation films and coating foods. Polylactic acid (PLA) is very common in the food industry due to is clear color and resistance to water. However, most polymers have a hydrophilic nature and start deteriorating when exposed to moisture. Biopolymers are also being used as edible films that encapsulate foods. These films can carry things like antioxidants, enzymes, probiotics, minerals, and vitamins. The food consumed encapsulated with the biopolymer film can supply these things to the body. Packaging: The most common biopolymers used in packaging are polyhydroxyalkanoates (PHAs), polylactic acid (PLA), and starch. Starch and PLA are commercially available and biodegradable, making them a common choice for packaging. However, their barrier properties (either moisture-barrier or gas-barrier properties) and thermal properties are not ideal. Hydrophilic polymers are not water resistant and allow water to get through the packaging which can affect the contents of the package. Polyglycolic acid (PGA) is a biopolymer that has great barrier characteristics and is now being used to correct the barrier obstacles from PLA and starch. Water purification: Chitosan has been used for water purification. It is used as a flocculant that only takes a few weeks or months rather than years to degrade in the environment. Chitosan purifies water by chelation. This is the process in which binding sites along the polymer chain bind with the metal ions in the water forming chelates.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.